ArticleStem cell research & therapy2026
Mesenchymal stem cells reverse ovarian dysfunction by inhibiting autophagy in polycystic ovary syndrome mice.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a chronic inflammatory disorder that affects the reproductive health of 5%-18% of women of reproductive age worldwide. However, PCOS is yet to be completely cured. As a biomaterial that regulates the conditions of the female reproductive system, many studies have demonstrated that mesenchymal stromal cells (MSCs) have significant therapeutic potential for restoring impaired ovarian function. The purpose of the study was to examine the therapeutic benefits of human umbilical cord mesenchymal stromal cells (Huc-MSCs) in mice with dehydroepiandrosterone (DHEA)-induced PCOS and to assess their effects on ovulation, sex hormones, and the estrous cycle.
methodsFlow cytometry (FCM) was used to identify Huc-MSCs. The expression of the autophagy-related proteins LC3 II, Beclin1, and mammalian target of rapamycin (mTOR) was evaluated by Western blot (WB) and real-time quantitative polymerase chain reaction (RT-qPCR). Changes in the number of autophagosomes were assessed by transmission electron microscope (TEM). DHEA was subcutaneously injected into female C57BL/6J mice to develop a PCOS model. The morphological changes in the ovaries and the number of oocytes at various stages of development in PCOS mice were observed using hematoxylin and eosin (H&E) staining. The levels of sex hormones were measured using enzyme-linked immunosorbent assay (ELISA), and the estrous cycle of PCOS mice was monitored using vaginal smears.
resultsThe PCOS patient group exhibited significantly higher levels of ATG5 and Parkin than the control group and a significant increase in the number of autophagosomes in the GCs of PCOS patients compared with those of non-PCOS women. Huc-MSCs are capable of repairing the impaired estrous cycle in PCOS mice and decreasing the level of testosterone (T) and the ratio of luteinizing hormone (LH)/ follicle-stimulating hormone (FSH) (LH/FSH ratio). Huc-MSCs are also able to repair ovulatory functions and facilitate oocytes maturation in PCOS mice. Autophagy suppression can improve oocytes viability in mice. Huc-MSCs also can inhibit granulosa cell autophagy, promote oocytes development, maintain homeostatic hormone levels, and restore the estrous cycle in PCOS mice. Huc-MSCs have the potential to treat ovarian dysfunction in PCOS mice by inhibiting autophagy pathway. In KGN cells and in DHEA-induced PCOS mice, mTOR expression was significantly downregulated. Huc-MSCs treatment markedly upregulated mTOR levels.
conclusionsOur results suggest that Huc-MSCs improve ovarian dysfunction in PCOS by inhibiting autophagy, providing experimental evidence for the clinical application of hUC-MSCs and offering a new therapeutic approach for the treatment of PCOS.
Indexed as
Identifiers
42436566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.